Exelixis, Inc.

Exelixis is an oncology company that develops medicines for difficult-to-treat cancers. It offers CABOMETYX and COMETRIQ tablets and capsules for various types of cancer. The company also offers COTELLIC and MINNEBRO for specific forms of melanoma and hypertension. Exelixis is developing zanzalintinib and XB002, next-generation oral tyrosine kinase inhibitors. It has research collaborations and license agreements with several pharmaceutical companies. The company was incorporated in 1994 and is headquartered in Alameda, California.

Overview

Sector

Biotechnology

Target Price

62.5 USD

Current Price

36.9 USD

Potential

70%

Strengths

With an appreciation Potential of 69.17%, based on our fundamental analysis, it suggests the stock may be undervalued.
Current Price to Earnings Ratio (19.97) is lower than the sector mean (91.15).
The company has low debt. Net Debt to EBITDA Ratio is -0.03 and it is lower than the sector mean.
The company has high returns. ROIC (28.75%) is higher than the sector mean (6.02%).
EV/EBIT (15.05) is lower than the sector mean.
Price to free cash flow (16.42) is lower than the sector mean.
Strong EBITDA Margin of 27.94%.

Weaknesses

No significant weaknesses identified based on the analyzed metrics.

Key Financial Data

Indicator	Value
PER	19.9
EV/EBITDA	12.9
Price/Free Cash Flow'	16.4
ROIC	28.7%
Net Debt/EBITDA	-0.0